Tim Friede
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
Koch J, Leha A, Bidner H, Cordts I, Dorst J, Günther R, Zeller D, Braun N, Metelmann M, Corcia P, Depla E, Weydt P, Meyer T, Grosskreutz J, Soriani M, Attarian S, Weishaupt J, Weyen U, Kuttler J, Zurek G, Rogers M, Feneberg E, Deschauer M, Neuwirth C, Wuu J, Ludolph A, Schmidt J, Remane Y, Camu W, Friede T, Benatar M, Weber M, Lingor P, ROCK-ALS Study group. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2024; 23:1133-1146.
01.11.2024Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
01.11.2024Lancet Neurol 2024; 23:1133-1146
Koch Jan Christoph, Leha Andreas, Bidner Helen, Cordts Isabell, Dorst Johannes, Günther René, Zeller Daniel, Braun Nathalie, Metelmann Moritz, Corcia Philippe, Depla Erik, Weydt Patrick, Meyer Thomas, Grosskreutz Julian, Soriani Marie-Hélène, Attarian Shahram, Weishaupt Jochen H, Weyen Ute, Kuttler Josua, Zurek Gabriela, Rogers Mary-Louise, Feneberg Emily, Deschauer Marcus, Neuwirth Christoph, Wuu Joanne, Ludolph Albert C., Schmidt Jens, Remane Yvonne, Camu William, Friede Tim, Benatar Michael, Weber Markus, Lingor Paul, ROCK-ALS Study group
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
Lingor P, Koch J, Ludolph A, Frontini R, Blankenstein C, Bidner H, Kuzma-Kozakiewicz M, Benatar M, Günther R, Neuwirth C, Leha A, Hilgers R, Friede T, Camu W, Weber M, ROCK-ALS Investigators. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol 2019; 10:293.
27.03.2019ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
27.03.2019Front Neurol 2019; 10:293
Lingor Paul, Koch Jan C, Ludolph Albert, Frontini Roberto, Blankenstein Christiane, Bidner Helen, Kuzma-Kozakiewicz Magdalena, Benatar Michael, Günther René, Neuwirth Christoph, Leha Andreas, Hilgers Reinhard, Friede Tim, Camu William, Weber Markus, ROCK-ALS Investigators